A
Allorion Therapeutics
Next-generation precision medicine for oncology and autoimmune disease
About Allorion Therapeutics
Allorion Therapeutics is a biotechnology startup that specializes in the development of next-generation targeted drugs for cancer and autoimmune diseases. The company operates in the pharmaceutical market, specifically in the oncology and autoimmune sectors. The team at Allorion is composed of experts in cancer biology and drug development, which gives them a competitive edge in their field.
Read full description
The company's business model revolves around the development of novel small molecule drugs. They do this by selecting well-validated targets with clear clinical development routes and discovering their modulators with distinct mechanisms of action. Their innovative data and screening platforms play a crucial role in this process, as they allow for the identification of novel targets and chemicals.
Allorion also constructs chemical libraries, prioritizing allosteric and covalent modulators, and optimizes these libraries with the help of artificial intelligence (AI). This approach allows them to develop mutant selective and isoform-specific drugs in non-conventional ways, improving efficacy and preventing resistance.
The company's revenue is likely generated through the licensing and sale of their developed drugs to larger pharmaceutical companies or healthcare providers. They may also receive funding from research grants or investors interested in the biotech sector.
Allorion Therapeutics is based in Boston, with both office and lab facilities located in Natick, Massachusetts.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Natick, United States
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 71.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Core AI, Precision Medicine, Biotech and Pharma, AI Drug Discovery, Hard Tech, AI Applications, DT and LS
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2023 | $50M | $200M | 3SBio · Octagon Capital Partners · Elikon Venture · LongRiver Investments | ↗ |
| SERIES AOther financing | Nov 2021 | $40M | $160M | IDG Capital · TF Capital · Octagon Capital Partners · Firstred Capital | ↗ |
Growth signals
Latest recorded traffic for Allorion Therapeutics is 3.1K monthly website visits, up 72.2% over the last three months. Allorion Therapeutics's team declined 8.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Med-Fine Capital
Series A9 investors entered at this stage
Qiming Venture Partners
IDG Capital
TF Capital
Octagon Capital Partners
Firstred Capital- EVElikon Venture
INCE Capital
3SBio
LongRiver Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Allorion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allorion Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.